[弥凝治疗尿崩症。从鼻腔给药转换为口服给药]
[Treatment of diabetes insipidus with Minirin. Switch from nasal to oral administration].
作者信息
Czernichow P
机构信息
Hôpital Robert Debré, Service d'Endocrinologie Diabétologie Pédiatrique, Paris.
出版信息
Ann Endocrinol (Paris). 1998 Dec;59(5):407-9.
DDAVP (desmopressin, Minirin is now available in tablet form. We studied the switch from nasal to oral administration in patients taking DDAVP for diabetes insipidis. A retrospective analysis included 56 patients. Mean nasal dosage was found to be 20.4 micrograms desmopressin and mean oral dosage was 417 micrograms. This gave a dosage ratio of about 20, in agreement with current data on the drug's bioavailability. In addition, the daily dose was fractioned more often with oral administration than with nasal administration. This study prepares the way for a prospective study needed to better define the conditions for oral administration of DDAVP (Minirin).
去氨加压素（弥凝）现已有片剂形式。我们对正在服用去氨加压素治疗尿崩症的患者从鼻腔给药转换为口服给药进行了研究。一项回顾性分析纳入了56例患者。发现去氨加压素的平均鼻腔给药剂量为20.4微克，平均口服剂量为417微克。这得出的剂量比约为20，与该药物生物利用度的现有数据一致。此外，与鼻腔给药相比，口服给药时每日剂量的分次给药更为频繁。这项研究为进一步明确去氨加压素（弥凝）口服给药条件所需的前瞻性研究奠定了基础。
Zotero 插件